Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | NPC1 | O15118 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | HPGD | P15428 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100361 | 1.00 | CYP2D6 (0.96) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL100360 | 1.00 | CYP2D6 (0.96) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL8136171 | 0.98 | CYP2D6 (0.93) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL7446968 | 0.98 | CYP2D6 (0.93) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9277459 | 0.98 | CYP2D6 (1.00) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| Pipradrol SCHEMBL156360 | 0.95 | CYP2D6 (0.87) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| Pipradrol SCHEMBL4057811 | 0.93 | CYP2D6 (0.90) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| Sulfuric Acid SCHEMBL9452303 | 0.92 | CYP2D6 (0.82) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL6295242 | 0.90 | CYP2D6 (0.79) | CYP2D6MAPK1KDM4ENPC1CYP1A2 | |
| SCHEMBL5054811 | 0.90 | CYP2D6 (0.79) | CYP2D6MAPK1KDM4ENPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-3995492-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2024-05-29 | — | — | EP | claimed |
| CN-113943317-B | Preparation method of MeCBS solid | 大连双硼医药化工有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-113816943-B | Resolution method of droxidopa key intermediate | 重庆圣华曦药业股份有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-114853662-B | Process for preparing chiral hydrazinopiperidine derivatives | 四川青木制药有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-113773297-B | Resolution method of droxidopa key intermediate | 重庆圣华曦药业股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-20220323380-A1 | DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | ISANAS AG (CH) | 2022-10-13 | — | — | US | claimed |
| US-6677462-B2 | S-(+)-4-METHOXY-6-PHENETHYL-5,6-DIHYDRO-PYRAN-2-ONE; PLANT EXTRACTS FOR NUTRACEUTICAL FOODS, TOPICAL OINTMENTS | KAVA PHARMACEUTICALS, INC. | 2004-01-13 | — | — | US | claimed |
| US-20030195366-A1 | Epoxidation process using amine catalysts | THE UNIVERSITY OF SHEFFIELD | 2003-10-16 | — | — | US | claimed |
| US-20030060633-A1 | Asymmetric synthesis of kavalactones | SYNTA PHARMACEUTICALS CORP. | 2003-03-27 | — | — | US | claimed |
| EP-1147099-A1 | EPOXIDATION PROCESS USING AMINE CATALYSTS | The University of Sheffield (GB) | 2001-10-24 | — | — | EP | claimed |
| WO-2000044735-A1 | EPOXIDATION PROCESS USING AMINE CATALYSTS | THE UNIVERSITY OF SHEFFIELD (GB) | 2000-08-03 | — | — | WO | claimed |
| US-5925666-A | DOPAMINE UPTAKE INHIBITORS; DRUG ABUSE AND DEPENDENCE, EATING DISORDERS, ATTENTION DEFICIT DISORDER, TOURETTE*S SYNDROME, GAMBLING | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-20 | — | — | US | claimed |
| WO-1999003467-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE DISORDERS USING PYRROLIDINE DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-01-28 | — | — | WO | claimed |
| WO-1998007653-A1 | CHIRAL HYDRIDE COMPLEXES | ZEELAND CHEMICALS, INC. (US) | 1998-02-26 | — | — | WO | claimed |
| WO-1997024030-A1 | PYRROLIDINE DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | claimed |
| EP-0453288-A1 | Enantiospecific synthesis of S(+)-5,6-dihydro-4-(R-amino)-4H thieno (2,3-B)thiopyran-2-sulfonamide-7,7-dioxide | MERCK & CO. INC. (US) | 1991-10-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060633-A1 | Asymmetric synthesis of kavalactones | GNE, KLK14, ALG8 | CYP2D6 388/4885MAPK1 4362/4885KDM4E 246/4885 |
| US-20030195366-A1 | Epoxidation process using amine catalysts | EPOR, POR, AOX1 | CYP2D6 26/4885MAPK1 2397/4885KDM4E 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.